000 03016cam a2200349 a 4500
003 EG-GiCUC
005 20250223032145.0
008 190108s2018 ua h f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aM.Sc
099 _aCai01.19.04.M.Sc.2018.Na.P
100 0 _aNahla Hamdy Abdasattar Heikal
245 1 0 _aPattern of care and treatment results of pancreatic adenocarcinomas /
_cNahla Hamdy Abdasattar Heikal ; Supervised Mostafa Mahmoud Alserafi , Ghada Mahmoud Sherif , Marwa Mahmoud Hussein Mahmoud
246 1 5 _aنمط الرعاية و نتائج علاج أورام البنكرياس السرطانية
260 _aCairo :
_bNahla Hamdy Abdasattar Heikal ,
_c2018
300 _a110 P. :
_bfacsimiles ;
_c25cm
502 _aThesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Oncology-Medical
520 _aBackground and aim: The aim of this work is to assess the pattern of care and treatment results of locally advanced and metastatic pancreatic adenocarcinomas regarding clinicopathological data, different therapeutic modalities given to Egyptian patients presented to the National cancer institute (NCI), Egypt, in the period from 2009 to 2013 and their survival parameters. Patients and methods: This is a retrospective cohort study of patients{u2019} files whom were diagnosed as locally advanced or metastatic pancreatic adenocarcinoma treated and followed up at the Medical oncology department, National cancer institute (NCI) in Egypt, during a 5-year period, from 2009 to 2013. Results: This study included 126 cases of locally advanced or metastatic pancreatic adenocarcinoma. Out of the 126 cases included, the male gender was predominant with 60.3%. The majority of the cases were over the age of 55 (about 53% of cases). About 49% had an ECOG PS 1, while only 1.5% was of PS 4. The reported co-morbidities were 26.2% DM, while only 7.9% were smokers. Regarding the initial presentation, 23 suffered from jaundice, 8 had ascites and 29 reported pain. Most of the patients (56.3%) were inoperable. The liver was the commonest site of metastasis (78.48%). Of the first line chemotherapy, 93% was Gemcitabine-based, with only 1 as Neo-adjuvant. The average number of first line cycles was 1-2 cycles with only 1 patient reaching 8 cycles. Only six patients achieved CR after the first line, while 77.6% had progressive disease. Eight patients went for second line chemotherapy, 3 for third line chemotherapy and only 1 patient went for fourth line chemotherapy
530 _aIssued also as CD
653 4 _aDiabetes mellitus
653 4 _aJaundice
653 4 _aPancreatic adenocarcinoma
700 0 _aGhada Mahmoud Sherif ,
_eSupervisor
700 0 _aMarwa Mahmoud Hussein Mahmoud ,
_eSupervisor
700 0 _aMostafa Mahmoud Alserafi ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aSamia
_eCataloger
942 _2ddc
_cTH
999 _c69455
_d69455